Oleic acid
USP/1478130 - United States Pharmacopeia (USP) Reference Standard
Synonym: cis-9-Octadecenoic acid; Elainic acid
CAS Number: 112-80-1
Empirical Formula (Hill Notation): C18H34O2
Molecular Weight: 282.46
MDL Number: MFCD00064242
Linear Formula: CH3(CH2)7CH=CH(CH2)7COOH
Product Type: Chemical
| API family | oleic acid |
| application(s) | USP Biologics pharmaceutical (small molecule) |
| bp | 194-195 °C/1.2 mmHg (lit.) |
| density | 0.89 g/mL at 25 °C (lit.) |
| form | liquid |
| format | neat |
| grade | pharmaceutical primary standard |
| InChI | 1S/C18H34O2/c1-2-3-4-5-6- |
| InChI key | ZQPPMHVWECSIRJ-KTKRTIGZSA |
| manufacturer/tradename | USP |
| mp | 13-14 °C (lit.) |
| refractive index | n |
| SMILES string | CCCCCCCCC=C/CCCCCCCC(O)= |
| vapor pressure | 1 mmHg ( 176 °C) |
| Analysis Note: | These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. |
| Application: | Oleic acid USP reference standard suitable for use in specified USP compendial quality tests and assays. Also used to prepare standard solution during the assay and identification according to the given below monographs of United States Pharmacopeia (USP): • Oleic Acid • Coix Seed • Coix Seed Powder |
| General description: | Oleic acid, an unsaturated fatty acid, is commonly utilized in microbiological processes for the formulation of lipid-based drug delivery systems, particularly in vaccines and biologics. It aids in the stabilization of emulsions, which is critical in the preparation of vaccines and other injectable biologics. Additionally, oleic acid plays a role in the optimization of the pharmacokinetics of biologically-derived therapies. The United States Pharmacopeia (USP) provides quality standards for biologics to ensure their safety, efficacy, and quality throughout the manufacturing process. These standards assist manufacturers in adhering to regulatory requirements and help safeguard public health by reducing risks associated with biologics. |
| General description: | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia   . |
| Other Notes: | Sales restrictions may apply. |
| Other Notes: | This product is part of USP Biologics Program. |
| Other Notes: | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pha |
| Other Notes: | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia . |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| bp | 194-195 °C/1.2 mmHg (lit.) |
| mp | 13-14 °C (lit.) |
| Density | 0.89 g/mL at 25 °C (lit.) |
| Refractive Index | n |
| UNSPSC | 41116107 |